Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fiboflapon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP known ✓ | P20292 | 20/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 5/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 1/20 | 1.00 |
| ▸ | LTC4S | Q16873 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fiboflapon SCHEMBL29379276 | 1.00 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL29723363 | 1.00 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL1254873 | 0.99 | ALOX5AP (0.99) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL29504643 | 0.99 | ALOX5AP (0.99) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL28358195 | 0.99 | ALOX5AP (0.99) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL167903 | 0.94 | ALOX5AP (0.90) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL12526775 | 0.94 | ALOX5AP (0.90) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL4365681 | 0.94 | ALOX5AP (0.89) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL1394760 | 0.94 | ALOX5AP (0.88) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL29063029 | 0.94 | ALOX5AP (0.88) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | AUTOIMMUNE PHARMA LLC (US) | 2020-05-14 | — | — | US | claimed |
| WO-2018152405-A1 | REDUCTION OF PRO-INFLAMMATORY HDL USING A LEUKOTRIENE INHIBITOR | AUTOIMMUNE PHARMA LLC (US) | 2018-08-23 | — | — | WO | claimed |
| US-8710081-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-04-29 | — | — | US | claimed |
| US-20140018394-A1 | 5-LIPOXGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AUTOIMMUNE PHARMA LLC | 2014-01-16 | — | — | US | claimed |
| US-20120232031-A1 | INJECTABLE FORMULATIONS FOR INTRA-ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | claimed |
| EP-2490689-A2 | INJECTABLE FORMULATIONS FOR INTRA- ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | Panmira Pharmaceuticals, LLC (US) | 2012-08-29 | — | — | EP | claimed |
| EP-1943219-B8 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | PANMIRA PHARMACEUTICALS LLC (US) | 2012-03-07 | — | — | EP | claimed |
| US-20120027842-A1 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR ADMINISTRATION TO AN EYE | AMIRA PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | claimed |
| EP-2404904-A1 | 5-lipoxygenase-activating protein (FLAP) inhibitors | Amira Pharmaceuticals, Inc. (US) | 2012-01-11 | — | — | EP | claimed |
| US-20110311613-A1 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS | AMIRA PHARMACEUTICAL, INC. (US) | 2011-12-22 | — | — | US | claimed |
| EP-2285803-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR | Amira Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | claimed |
| WO-2010075314-A2 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | claimed |
| WO-2010075315-A2 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR ADMINISTRATION TO AN EYE | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | claimed |
| WO-2010068311-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-20090291981-A1 | 5-Lipoxygenase-Activating Protein Inhibitor | AMIRA PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | claimed |
| US-20090192171-A1 | 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | US | claimed |
| EP-1943219-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2008-07-16 | — | — | EP | claimed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | claimed |
| WO-2007056021-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | ALOX5AP 4/4885PTGS1 27/4885ALOX5 1/4885 |
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | LTB4R, LTC4S, LTB4R2 | ALOX5AP 35/4885PTGS1 22/4885ALOX5 7/4885 |
| US-20090192171-A1 | 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors | ALOX5, ALOX15B, ALOX15 | ALOX5AP 4/4885PTGS1 27/4885ALOX5 1/4885 |
| US-20120027842-A1 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR ADMINISTRATION TO AN EYE | FEN1, SERPINB1, EYA2 | ALOX5AP 100/4885PTGS1 264/4885ALOX5 69/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | ALOX5AP 4/4885PTGS1 27/4885ALOX5 1/4885 |
| US-20090291981-A1 | 5-Lipoxygenase-Activating Protein Inhibitor | ALOX5, LTA4H, ALOX5AP | ALOX5AP 3/4885PTGS1 35/4885ALOX5 1/4885 |
| US-20140018394-A1 | 5-LIPOXGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LTA4H, ALOX5AP | ALOX5AP 3/4885PTGS1 38/4885ALOX5 1/4885 |
| US-20110311613-A1 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS | TSLP, SUCLG1, SERPINB1 | ALOX5AP 96/4885PTGS1 495/4885ALOX5 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.